# Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes

> **NCT00104806** · PHASE2 · TERMINATED · sponsor: **Wake Forest University Health Sciences** · enrollment: 5 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms

## Interventions

- **DIETARY_SUPPLEMENT:** cholecalciferol
- **DRUG:** arsenic trioxide

## Key facts

- **NCT ID:** NCT00104806
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-11
- **Primary completion:** 2006-01
- **Final completion:** 2010-05
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** sponsor discontinues support
- **Last updated:** 2018-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00104806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00104806, "Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00104806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*